Professor of Cardiology, Coronary and Structural Interventional Cardiologist, @SRIHER & @SRMC, Chennai. #tweetsaremyownviews
Chennai, India
Joined June 2016
- Tweets1.2K
- Following892
- Followers1.5K
- Likes1.9K
S Nagendra Boopathy retweeted
When a cath lab crisis hits, what should happen first? @MortonKern outlines practical steps for managing no-reflow, coronary perforation, acute vessel closure, & vascular access complications + who to call & communication under pressure. hubs.ly/Q04yB3XJ0 #cardiotwitter
S Nagendra Boopathy retweeted
Medicine and the Fight Against Death: A Journey of Success and Innovation!
#EHJ #aging #cure #genetics #cardiovascular #medicine #cardiotwitter @ESC_Journals @escardio
ow.ly/fyBg50ZRRnu
S Nagendra Boopathy retweeted
Incidence of refibrillation and shock-resistant ventricular fibrillation during OHCA when treated with a public access defibrillator: implications for CPR timing in lay rescuer-treated OHCA.@drkarthik2010 @BoopathyCardio @BelfastTrust
bit.ly/4dpHUDl
First study from India Comparing VFFR and FFR. @SRIHER_Official @SRMC_official @Pie_Med_Imaging @harilalith @JudahArul @AshishHShah3 @CsiChennai
sciencedirect.com/science/ar…
Post REVIVED BCIS-2 period: does CMR play a role in the decision made by heart teams for revascularization ? It was evaluated by us. In this study. Unsurprisingly, we still incline towards CMR for decision which helps in greater agreement in therapeutic decisions. Thanks to all the co-authors
@SRIHER_Official @SRMC_official @cardiosadha2 @drsathish82 @drsalmans @VadiveluRamali2 @DrGJustinPaul1
frontiersin.org/journals/car…
Outcomes of Concomitant PCI and TAVR Versus TAVR Alone in Patients with Severe Aortic Stenosis: A Retrospective Study.
@drrao_TAVI @cardiosadha2 @tavrkapadia @RajMakkar4 @ACCinTouch @GilbertTangMD @ccclivecases @CsiChennai @SRIHER_Official @SRMC_official .
kwnsfk27.r.eu-west-1.awstrac…
Happy to share our recent publication on CMR and its impact on heart team decision. @cardiosadha2 @AshishHShah3
@drsalmans @drsathish82 @harilalith &Dr Jebaraj. @SRIHER_Official @SRMC_official
frontiersin.org/journals/car…
We often use overlapping stents from different platforms in clinical practice. We were interested in understanding what actually happens at the interface between such heterogeneous stents compared with homogeneous stent overlaps. In our retrospective, two-centre study, we found that there was no major difference between heterogeneous and homogeneous stent overlaps in terms of the outcomes we evaluated. @SRIHER_Official @SRMC_official @drsalmans @aiims_newdelhi
doi.org/10.1002/ccd.70781
S Nagendra Boopathy retweeted
In this #JACCAsia editorial, the authors review the "SMuRF paradox" after #AMI.
Future risk stratification may require integrating traditional CV risk factors with inflammatory, genetic, & psychosocial markers. jacc.org/doi/10.1016/j.jacas…
#cvPrev #MACE @BoopathyCardio @harilalith
S Nagendra Boopathy retweeted
Effect of pictorial-based information about atherosclerosis on adherence to lifestyle recommendations: results from the VIPVIZA randomised controlled trial.
@BoopathyCardio @drkarthik2010 @LoginRajeevAgar @umeauniversity
bit.ly/4pD38Cl
S Nagendra Boopathy retweeted
Non-invasive diagnosis of left main coronary artery disease in chronic coronary syndrome patients: diagnostic utility of an approach using clinical and ECG stress testing
doi.org/10.1093/eurheartj/eh…
#CCS #CAD #LM #cardiotwitter @ESC_Journals @escardio
S Nagendra Boopathy retweeted
This article by @AndrewFoy82 is a must read for anyone in medicine. External validity of clinical trials may be one of the most under-appreciated concepts in medicine especially when it comes to heart failure therapy. open.substack.com/pub/sensib…
S Nagendra Boopathy retweeted
From humble beginnings to leading one of the nation's premier cardiovascular programs, Dr. Samin Sharma and I talk about the journey that shaped his career and what lies ahead in his new role as Chief of Cardiology at Mount Sinai.
clinicaltrialresults.org/fro…
S Nagendra Boopathy retweeted
Congratulations to Samin K. Sharma, MD, who has been appointed Chief of Clinical Cardiology at Mount Sinai Hospital in New York City.
S Nagendra Boopathy retweeted
Mineralocorticoid receptor antagonists in heart failure with sustained monomorphic ventricular tachycardia: comparative analysis of spironolactone versus eplerenone.@drkarthik2010 @BoopathyCardio @SanjitSJolly @hfaimedia
bit.ly/49qoex1
S Nagendra Boopathy retweeted
The ideal puncture site can be identified only by echo!!!!! I think that transesophageal or intracardiac #echofirst guidance should become the only way to perform transeptal puncture!
Where is the ideal site for transseptal puncture?
In the 40° RAO projection, a pigtail catheter placed in the non-coronary aortic cusp helps define the posterior border of the aortic root. The optimal puncture site (X) is typically located 1–3 cm inferior to the posterior boundary of the aortic root, within the fossa ovalis region.
Accurate localization is critical to safely access the left atrium while minimizing the risk of aortic puncture and other complications.
Reference: Croft CH, Lipscomb K. Modified technique of transseptal left heart catheterization. J Am Coll Cardiol. 1985;5(4):904–910.
S Nagendra Boopathy retweeted
A p-value below the noninferiority threshold is not a free pass. Noninferiority margins need clinical justification, and intention-to-treat and per-protocol analyses should ideally point in the same direction. As DES outcomes continue to improve, noninferiority trials of coronary devices become increasingly fragile.
